Status: Recruiting
Efficacy and Safety of SR1375 in Adult Patients With CAP
This is a phase 2 study to evaluate the efficacy and safety of SR1375 in hospitalized adult patients with CAP. Patients will receive SR1375 or placebo for 8 weeks. The study duration for each patient is up to 10 weeks.
Participants needed: 240
Trial details
Phase: Phase 2Age: 18-85Biological sex: AllType: InterventionalSponsor: Shanghai SIMR Biotechnology Co., Ltd.Updated: Jul 9, 2025Locations: 29
Eligibility criteria
The subject or their legally acceptable representative (LAR) has voluntarily sig... [+8]
Patients who are currently receiving or are expected to require ECMO treatment w... [+10]